Temocapril API is a synthetic angiotensin-converting enzyme (ACE) inhibitor prodrug used in pharmaceutical formulations for the management of hypertension. After administration, Temocapril is converted into its active metabolite, temocaprilat, which inhibits angiotensin-converting enzyme and contributes to the reduction of blood pressure.
Temocapril is a chiral small-molecule pharmaceutical compound with the molecular formula C₂₃H₂₈N₂O₅S₂ and a molecular weight of approximately 476.61 g/mol. Its pharmaceutical activity is associated with modulation of the renin-angiotensin system.
Swapnroop provides Temocapril API for pharmaceutical formulation, development, analytical research and manufacturing applications with a quality-focused approach to API production and documentation.
Temocapril belongs to the ACE inhibitor class and acts as a prodrug. Its active metabolite, temocaprilat, inhibits ACE, reducing the conversion of angiotensin I into angiotensin II.
Through this mechanism, Temocapril supports vasodilation and reduction of blood pressure. It has been used as an antihypertensive pharmaceutical ingredient.
Temocapril is a synthetic organic compound containing nitrogen, oxygen and sulfur atoms. Its molecular structure contains a thiazepine ring system, thiophene group and ester functionality.
Key Chemical Information
Product Name: Temocapril
CAS Number: 111902-57-9
Molecular Formula: C₂₃H₂₈N₂O₅S₂
Molecular Weight: 476.61 g/mol
API Type: Synthetic Small-Molecule API
Therapeutic Class: ACE Inhibitor
Active Metabolite: Temocaprilat
ATC Classification: C09AA14
Pharmaceutical Application: Antihypertensive Therapy
Physical Form: Solid API
Temocapril Hydrochloride is a separate salt form of Temocapril and should be maintained as a distinct product specification.
Temocapril Hydrochloride has CAS Number 110221-44-8, molecular formula C₂₃H₂₉ClN₂O₅S₂ and molecular weight approximately 513.07 g/mol.
Temocapril and Temocapril Hydrochloride should not be combined within the same API specification because their chemical composition and molecular weights are different.
Temocapril is primarily associated with pharmaceutical treatment of hypertension. Its active metabolite, temocaprilat, acts through ACE inhibition and affects the renin-angiotensin system.
Its pharmaceutical applications include:
• Antihypertensive formulations
• ACE inhibitor drug development
• Cardiovascular pharmaceutical formulations
• Generic formulation development
• Pharmaceutical analytical research
• Quality-control studies
Temocapril API can be evaluated using validated analytical methods suitable for pharmaceutical applications.
Typical quality-control parameters include:
• Appearance
• Identification by IR
• Identification by HPLC
• Assay by HPLC
• Related substances
• Individual impurities
• Total impurities
• Water content
• Loss on drying
• Residue on ignition
• Elemental impurities
• Residual solvents
• Chiral purity
• Specific rotation, where applicable
• Melting range, where applicable
• Solubility
• Microbial quality, where applicable
Swapnroop provides Temocapril API for pharmaceutical formulation, development and manufacturing requirements.
Our approach focuses on controlled manufacturing processes, analytical characterization and quality documentation suitable for pharmaceutical customers.
Temocapril can be supplied according to agreed technical specifications and applicable quality requirements for pharmaceutical development and manufacturing applications.
Temocapril API should be packed in suitable pharmaceutical-grade, well-closed containers that protect the material from moisture, contamination and environmental exposure.
Storage conditions should follow validated stability data and the applicable product specification. Customers should follow the storage conditions stated in the batch-specific Certificate of Analysis and technical documentation.
Depending on product grade and customer requirements, documentation may include:
• Certificate of Analysis (CoA)
• Safety Data Sheet (SDS)
• Product Specification
• Analytical Test Methods
• Batch Documentation
• Technical Data Sheet
• Stability Information, where available
• Regulatory Documentation, where applicable
• Manufacturing Documentation, subject to availability
• Quality-focused API manufacturing
• Controlled production processes
• Analytical testing and characterization
• Batch-specific quality documentation
• Pharmaceutical formulation support
• Technical documentation support
• Consistent quality approach
• Pharmaceutical development support
• Manufacturing support for domestic and international requirements
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.2% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 3.5 – 5.5 |
| Individual Impurity | ≤ 0.5% |
| Total Impurities | ≤ 1.5% |
| Water Content | NMT 1.0% |